Influence of polyhedral oligomeric silsesquioxanes (POSS) on blue light-emitting materials for OLED
摘要:
By using Heck polycondensation, we have synthesized carbazole-based alt-copolymers tethered with polyhedral oligomeric silsesquioxanes (POSS), which had well-defined architectures, similar polymerization degrees and the different contents of POSS. The effect of POSS content and the length of the side chain containing FOSS on the electroluminescence properties of these polymers were investigated. POSS particles in these alt-copolymers showed excellent dispersity and prevented the interchain aggregation of polymers in film state well. Besides, POSS benefited charge balance by increasing the electron current density, which led to a higher luminance and current efficiency, as well as purer blue light-emitting. (C) 2014 Elsevier Ltd. All rights reserved.
Electropolymerization of Metal Clusters Establishing a Versatile Platform for Enhanced Catalysis Performance
作者:Yi‐Man Wang、Jinmeng Cai、Qian‐You Wang、Yao Li、Zhen Han、Si Li、Chun‐Hua Gong、Shan Wang、Shuang‐Quan Zang、Thomas C. W. Mak
DOI:10.1002/anie.202114538
日期:2022.3
A series of metal-cluster hybrid materials was successfully fabricated by using the electropolymerization (EP) method. Poly-metal clusters in an extended conjugated network establish an electron transport highway to catalytic sites. The improvement in catalytic performance in poly-metal clusters was demonstrated by electrocatalytic reduction of nitrate (NO3−) to ammonia (NH3) and photocatalytic chemical
采用电聚合(EP)方法成功制备了一系列金属簇杂化材料。扩展共轭网络中的多金属簇建立了通往催化位点的电子传输高速公路。通过将硝酸盐 (NO 3 - )电催化还原为氨 (NH 3 ) 和光催化化学战模拟物降解实验证明了多金属簇中催化性能的改进。
[EN] HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE HDAC ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
申请人:UNIV ILLINOIS
公开号:WO2011011186A2
公开(公告)日:2011-01-27
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.